ADIL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adial Pharmaceuticals Inc (ADIL) is not a good buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, the financial performance is weak, and there are no strong positive catalysts or trading signals to suggest immediate upside potential. The stock's recent performance and analyst rating adjustments also reflect challenges. Given the user's preference for long-term investment and the lack of compelling reasons to invest now, holding off on purchasing ADIL is recommended.
The technical indicators for ADIL are bearish. The MACD is below 0 and negatively contracting, the RSI indicates the stock is oversold at 4.003, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 2.94, with resistance levels at 5.066 and 5.722. Historical patterns suggest a 70% chance of further declines in the short term (-1.3% in the next day, -1.63% in the next week, -4.42% in the next month).
The analyst maintains a Buy rating, citing potential opportunities in combating substance abuse and a possibly favorable regulatory environment. Congressional activity in support of substance abuse initiatives could be a future catalyst.
The analyst significantly reduced the price target from $37.50 to $8 due to a reverse split and expected dilution. The financial performance is weak, with a significant drop in EPS (-78.95% YoY) and net income (-18.17% YoY). There are no recent news updates, insider or hedge fund trading trends, or congress trading activity to suggest positive sentiment. The stock is in a bearish technical trend.
In Q3 2025, Adial Pharmaceuticals reported no revenue growth (0% YoY) and a net income drop of -18.17% YoY to -$1,793,651. EPS fell sharply by -78.95% YoY to -0.08. Gross margin remained at 0%. Overall, the financials reflect significant challenges and no growth momentum.
Maxim recently lowered the price target from $37.50 to $8 while maintaining a Buy rating. The reduction reflects concerns over a reverse split and expected dilution, though the analyst remains optimistic about the AUD opportunity and regulatory environment.
